Category: St. Jude MedicalSyndicate content

BSX loses $309M judgment in patent war with the family of Dr. Michel Mirowski | Medtech legal news for the week of September 29, 2014

September 29, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific loses $309 million judgment in Mirowski patent war; Ex-Advanced Medical Optics CEO Mazzo indicted in insider trading case; Appeals court denies BD bid to revisit loss to Retractable Technologies; Ackman threatens to sue Allergan again over potential Salix deal; Judge upholds $30M infringement ruling against NuVasive, cancels trademark

Boston Scientific loses $309 million judgment in Mirowski patent war

September 24, 2014 by Brad Perriello

Analyst: Boston Scientific could take CRM lead

September 25, 2014 by Alex Soule

Despite Boston Scientific having yet to debut a pacemaker that nestles inside the heart itself, an analyst said the company may be best positioned to capitalize on sales of such devices.

Analyst: Boston Scientific could take pacer lead

Boston Scientific loses $309 million judgment in Mirowski patent war

September 24, 2014 by Brad Perriello

Boston Scientific loses a $309 million judgment in its long-running patent war with Mirowski Family ventures over cardiac pacemaker technology.

Boston Scientific loses $309 million judgment in Mirowski patent war

UPDATED Sept. 25, 2014, with comment from Boston Scientific.

St. Jude chases MRI-friendly labeling for its CRM devices

September 22, 2014 by Arezu Sarvestani

St. Jude Medical lands European approval to market its Tendril STS and IsoFlex Optim leads as safe for MRI scanning, adding that the company's just getting started on a larger MRI-safe campaign.

E.U. regulators dub St. Jude's Tendril STS, IsoFlex Optim leads safe with MRI

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup

September 17, 2014 by Arezu Sarvestani

Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.

TCT 2014 Roundup

Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.

Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Study: CardioMEMs implanted heart monitor safe for renal failure patients

September 16, 2014 by Arezu Sarvestani

New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.

Study: CardioMEMS' implanted sensor safe for renal failure patients

St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp